You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,980,966

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,980,966

Title:	Combinations of cancer therapeutics
Abstract:	The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-- quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
Inventor(s):	Huck; Bayard R. (Sudbury, MA), Wilker; Erik (Lexington, MA), Machl; Andreas (Cambridge, MA), Kaleta; Remigiusz (Groton, MA)
Assignee:	Merck Patent GmbH (Darmstadt, DE)
Application Number:	15/128,045
Patent Claims:	1. A method for the prophylaxis or treatment of cancer comprising administering to a subject 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-- quinazoline-8-carboxylic acid amide, or physiologically acceptable salts thereof, and a Her2 inhibitor, or physiologically acceptable salts thereof, wherein the cancer is selected from the group consisting of breast, gastric, and uterine. 2. The method according to claim 1 wherein in the cancer is human breast cancer. 3. The method according to claim 1, wherein 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-- quinazoline-8-carboxylic acid amide and the Her2 inhibitor are administered simultaneously. 4. The method according to claim 1, wherein 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-- quinazoline-8-carboxylic acid amide and the Her2 inhibitor are administered sequentially. 5. The method according to claim 4, wherein the Her2 inhibitor is administered first. 6. The method according to claim 2, wherein 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-- quinazoline-8-carboxylic acid amide and the Her2 inhibitor are administered simultaneously. 7. The method according to claim 2, wherein 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-- quinazoline-8-carboxylic acid amide and the Her2 inhibitor are administered sequentially. 8. The method according to claim 7, wherein the Her2 inhibitor is administered first. 9. The method of any one of claim 1-5 or 6-8, wherein the Her2 inhibitor is trastuzumab. 10. The method of any one of claim 1-5 or 6-8, wherein the Her2 inhibitor is lapatinib.

Details for Patent 9,980,966

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.